In the elderly, isolated systolic hypertension (ISH) is a particularly good predictor of subsequent cardiovascular events. The purpose of this article is to review the evidence provided by the Systolic Hypertension Elderly Program (SHEP) and the Systolic Hypertension in Europe Study (Syst-Eur) on the benefits of lowering systolic blood pressure (SBP) and to report on the preliminary findings of the Maracaibo Aging Study (MAS) on ISH. These two trials, the SHEP using chlorthalidone and atenolol as step 2 and the Syst-Eur using nitrendipine and hydrochlorothyazide as step 2, demonstrated a decrease of more than 30% for all cardiovascular complications, including stroke and coronary events. MAS is a population-based study that included all the subjects older than 55 years of age that resided in a defined area of the city of Maracaibo. There was a high prevalence of ISH (45.7%) being higher among women than
Introduction
High blood pressure is a public health problem associated with significant risk for coronary heart disease, stroke, and other cardiovascular diseases. By middle or old age, systolic blood pressure (SBP) is more strongly related to cardiovascular complications than diastolic blood pressure (DBP), and may be used to predict risk for coronary heart disease, cardiovascular disease, stroke, and associated deaths. 1, 2 In the elderly, isolated systolic hypertension (ISH), defined as SBP у140 mm Hg DBP Ͻ90 mm Hg, is a particularly good predictor of subsequent cardiovascular events. 3 Although there has been some concern that antihypertensive medication could be associated with an increased risk for adverse events in this population, 4 ,5 the benefits of its indication for elderly patients with ISH have been demonstrated in several major trials. 6, 7 The
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Risk reduction associated with lowering SBP
The Systolic Hypertension Elderly Program (SHEP) 6 was a double-blind, randomised, placebo-controlled trial of treatment for ISH in subjects у60 years of age. Its primary and secondary objectives were to determine whether antihypertensive drugs reduce risk of stroke (non-fatal and fatal) and cardiovascular morbidity and mortality, respectively. The drugs used were: chlorthalidone as step 1 medication and atenolol or matching placebo was added as the usual step 2 drug. Mean SBP levels were substantially lower throughout the trial for the active treatment group than for the placebo group by 11 to 14 mm Hg. Mean DBP was reduced more in the active treatment group than in the placebo group by about 3 to 4 mm Hg, and the goal blood pressure was reached by 65-72% subjects in the active treatment group but only by 32-40% in the placebo group. With a mean follow-up of 4.5 years, the cumulative rates of stroke were 5.5 per 100 participants for the active treatment group and 9.2 per 100 for the placebo group; based on proportional hazards regression analysis, relative risk was 0.64 (95% confidence interval (CI): 0.50 to 0.82; P = 0.0003). The absolute reduction in 5-year risk of stroke was 30 events per 1000 participants. The 36% reduction in stroke incidence is similar to that found in trials of drug therapy for diastolic hypertension. 8, 9 In SHEP for all cardiovascular events the reduction of the incidence was 32% for the active treatment group. This is an absolute benefit at 5 years of 55 events per 1000 participants. Moreover, the SHEP decrease of 27% in incidence of non-fatal myocardial infarction plus coronary heart disease death for the active treatment group is similar to results of the Hypertension Detection and Follow-up Program 10 and greater than those in other trials in which the overall reduction in incidence of major coronary events was 14% (95% CI, 4% to 24%). 8 The benefits of antihypertensive treatment in older patients with ISH (у60 years of age) have also been demonstrated in the Systolic Hypertension in Europe Study (Syst-Eur Study). 7 The overall number of patients, age and entry SBP were similar to the SHEP trial and the median follow-up was 24 months. Each trial included a large number of diabetic patients (11-12%), with a combined total of 1075. Active treatment consisted of nitrendipine (10 to 40 mg per day), then hydrochlorothiazide (12.5 to 25.0 mg per day) as required to achieve a goal sitting SBP of Ͻ150 mm Hg. At the median 2-year followup, sitting SBP decreased by a mean of 13 mm Hg in the placebo group (n = 2297) compared with 23 mm Hg in the active treatment group (n = 2398). Mean DBP decreased by 2 mm Hg in the placebo group and 7 mm Hg in the active treatment group. Mean difference between groups in sitting SBP and DBP were 10.1 and 4.5 mm Hg, respectively. The incidence of fatal and non-fatal stroke combined, the primary end point, was decreased in the active treatment group by 42% (P = 0.0003). Fatal and non-fatal cardiac end points combined, including sudden death, were decreased by 26% (P = 0.03). In the active treatment group, reductions were also seen in heart failure (non-fatal 36%, P = 0.06). On the basis of these event rates observed in the placebo group, the data collected in this trial indicate that treatment of 1000 elderly patients with ISH for 5 years could prevent 29 strokes or 53 major cardiovascular events. The incidence of neoplasms, bleeding and the rates of non-cardiovascular current diseases occurred with a similar incidence in active treatment and placebo groups.
In conclusion, these studies showed a significant reduction in stroke and cardiovascular events associated with lowering SBP. Little has been published in regard to the association between ISH and dementia. [11] [12] [13] [14] The Syst-Eur Study reported that antihypertensive treatment was associated with Journal of Human Hypertension lower incidence of dementia, diagnosed using the Minimental State Examination Test. 15 In the Maracaibo Aging Study (MAS) a primary objective was to assess the impact of cardiovascular functioning on cognitive status in subjects older than 55 years, therefore the association between SBP and dementia was studied.
Preliminary report of the Maracaibo Aging Study (MAS)
MAS is a population-based study undertaken in a defined area of Maracaibo, that included all subjects у55 years of age. All the participating subjects underwent the same cardiovascular, neuropsychiatric and neuropsychological assessments. The basic diagnostic strategy for dementia was adapted from the Washington Heights Inwood Columbia Aging Project, 16, 17 and consisted of a semistructured neuropsychiatric interview and a neuropsychological battery. The diagnosis of dementia was based on criteria from the DSM-IV 18 after a consensus was reached in a diagnostic conference where physicians, neuropsychologists and social workers assisted. Casual blood pressure was measured using the oscillometric method with a Dinamap device (model 8100, Critikon, Tampa, FL, USA), and in approximately 50% of the subjects who were randomly selected, an ambulatory blood pressure monitor (ABPM) which also uses the oscillometric method (Space Labs, model 90207, Redmond, WA, USA) was performed over a 24-h period.
After assessing 1989 subjects, the prevalence of ISH was found to be 45.7% (Table 1) , higher than the frequency of diastolic and combined systolic/ diastolic hypertension (SDH). Among all hypertensives, women were more prone to suffer ISH than SDH ( Table 1 ). The subjects in the ISH and SDH groups were significantly older than in the normotensive patients, and ISH was more frequent with advancing age. Body mass index was higher for SDH and not for ISH when compared with normotensives. Cholesterol levels were higher for ISH while triglycerides and uric acid were significantly higher for SDH. Myocardial infarction was more common among SDH.
This prevalence of ISH is higher than that previously published. 3 The possible causes are: dietary factors, genetic factors and probably a higher prevalence of atherosclerosis, as in Venezuela, unlike the USA, there has been no decline in mortality for coronary artery disease, nor for cerebrovascular disease. It is well known that arterial stiffness leads to an increase in systolic and pulse pressures and a decrease in diastolic pressure.
ABPM and dementia in the elderly
Randomly assigned, a cross-sectional, communitybased study was carried out in 962 subjects, age у55 years from the MAS population to determine the Table 2 . It was demonstrated that SBP was related to cognitive derangement in this population measured by ABPM (while casual SBP and DBP were not). The blood pressure measured by casual method was not predictive of dementia, while when measured by ABPM was significantly associated for both ISH and SDH groups (OR: 3.41 and 2.81, respectively) ( Table 3) . Farmer et al 19 in a cohort from the Framingham study did not find an association between casual blood pressure and cognitive function; similar results were found by Glynn et al. 20 However, Kilander et al 21 and van Boxtel et al 22 , using ABPM, found an association between blood pressure measurement with cognitive dysfunction. Our findings provides further evidence that blood pressure measurement by ABPM more closely correlates with morbid events than casual blood pressure, and underscores the importance of SBP as a predictor of dementia.
Conclusion
There are clinical benefits of lowering elevated SBP to reduce the risk of cardiovascular events in elderly patients. As in the MAS study there was a higher prevalence of ISH in comparison with reports from other countries, further studies are required to assess the magnitude of this public health problem and factors associated with it in different latitudes. In addition the MAS study showed a strong correlation between high SBP and cognitive dysfunction and this was best demonstrated by using ABPM. Future research should address the impact of using ABPM or other modern diagnostic tests for diagnostic or prognostic purposes and to compare the thera-peutic effect of the different types of old and new antihypertensive drugs.
